DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lexiscan (Regadenoson) - Summary



Regadenoson is an A2A adenosine receptor agonist that is a coronary vasodilator [ see Clinical Pharmacology ].

Lexiscan™ (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

See all Lexiscan indications & dosage >>


Published Studies Related to Lexiscan (Regadenoson)

Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease--the ASSUAGE-CKD trial. [2013]
A subgroup analysis of the ASSUAGE trial suggested that the standardized intravenous aminophylline administration following regadenoson-stress leads to substantial attenuation of regadenoson adverse-effects in patients with severe chronic kidney disease (CKD)... In conclusion, the routine standardized administration of intravenous aminophylline in patients with severe CKD substantially reduces the frequency and severity of the adverse-effects associated with regadenoson-stress without changing the ischemic burden.

A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. [2012]
obstructive pulmonary disease (COPD)... CONCLUSIONS: This information may be helpful to physicians selecting a

Attenuation of the side effect profile of regadenoson: a randomized double-blinded placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging. "The ASSUAGE trial". [2012]
other adverse effects associated with regadenoson... CONCLUSIONS: This trial supports the routine administration of IV-aminophylline

Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study. [2011.02]
BACKGROUND: Caffeine attenuates the coronary hyperemic response to adenosine by competitive A(A) receptor blockade. This study aims to determine whether oral caffeine administration compromises diagnostic accuracy in patients undergoing vasodilator stress myocardial perfusion imaging (MPI) with regadenoson, a selective adenosine A(2A) agonist... CONCLUSION: The results of this study will show whether the consumption of caffeine equivalent to 2-4 cups of coffee prior to an MPI study with regadenoson affects the diagnostic validity of stress testing (ClinicalTrials.gov number, NCT00826280).

Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. [2009.04]
BACKGROUND: Adenosine and regadenoson increase heart rate (HR) when used as stress agents to produce coronary hyperemia due to direct sympathetic stimulation. We hypothesized that the HR response will be lower in patients with than in those without diabetes mellitus (DM)... CONCLUSIONS: The HR response to adenosine and regadenoson in patients with DM is blunted. If additional studies confer an agreement between traditional tests for determination of autonomic neuropathy and this measure, then examination of HR response to these agents during myocardial perfusion imaging might add prognostic power.

more studies >>

Clinical Trials Related to Lexiscan (Regadenoson)

Regadenoson Blood Flow in Type 1 Diabetes (RABIT¹D) [Not yet recruiting]
Cardiovascular disease (CVD) remains the major cause of mortality and morbidity in both type 1 (T1D) and type 2 (T2D) diabetes patients; modifications of traditional CVD risk factors have had a limited impact. This project called Regadenoson Blood flow in Type 1 Diabetes (RABITD) and is proposed as a sub-study of the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study, which has established a unique cohort of 656 T1D patients (age 20-55, minimal diabetes duration of 10 yrs) and 764 non-diabetic controls. This cohort is being followed for progression of coronary artery calcification (CAC) measured using the electron beam tomography (EBT) for development of clinical CVD. Participants have been well characterized during the baseline examination (4/00-3/02) and two follow-up re-examinations 3 and 6 years later. The study has provided important insights into the risk factors and possible prevention of premature CVD in T1D. We are proposing assess a subset of this population to determine vasodilatory reserve as it relates to early coronary atherosclerosis in T1D.

Hypothesis: that myocardial blood imaging (MBF) reserve can be measured in Type 1 DM using regadenoson stress cardiac magnetic resonance and that significantly reduced MBF is a marker of extensive artherosclerotic disease correlated to coronary arterial calcification, plaque formation and impaired vasodilatory reserve.

Specific Aims:

1. Determine the relationship between myocardial perfusion index (previously determined), regional CBF and invasively measured coronary flow reserve

2. Measure coronary blood flow using regadenoson stress CMR and determine the myocardial blood flow reserve in type 1 DM subjects compared to non-diabetic controls.

3. Determine the relationship between CBF reserve in vascular distributions to the degree of coronary arterial calcification.

4. Determine the severity of CBF blood flow reduction and the relationship to perfusion reserve measured by invasive coronary Doppler flow-wire under regadenoson between in type 1 DM subjects compared to non-diabetic controls.

Myocardial Blood Flow by PET and N-13 Ammonia During Regadenoson Stress [Recruiting]
The investigators propose to measure and compare regadenoson-induced hyperemic Myocardial Blood Flow (MBF) versus adenosine-induced hyperemic MBF, using PET N-13 Ammonia in healthy subjects. The protocol will provide clinically useful data for practice.

Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson [Recruiting]
This is a pilot study to determine whether the drug regadenoson can be used during magnetic resonance imaging to assess regions of poor blood flow to the heart.

The hypothesis of this study is that a single injection of regadenoson could be used instead of a standard adenosine infusion to produce coronary vasodilatation and demonstrate myocardial ischemia during first-pass perfusion cardiac MRI.

A Study to Assess Regadenoson Administration Following an Inadequate Exercise Stress Test as Compared to Regadenoson Alone for Myocardial Perfusion Imaging (MPI) Using Single Photon Emission Computed Tomography (SPECT) [Recruiting]
The purpose of this study is to demonstrate that the strength of agreement between single photon emission computed tomography (SPECT) imaging with regadenoson following inadequate exercise stress testing and SPECT imaging with regadenoson alone is not inferior to the strength of agreement between two sequential regadenoson SPECT images without exercise.

Regadenoson to Achieve Maximal Hyperemia for Fractional Flow Reserve in the Catheterization Lab [Recruiting]
The purpose of this study is to determine if regadenoson is as safe and effective as adenosine when used in the cardiac catheterization lab during measurement of coronary flow reserve and fractional flow reserve. The study hypothesis is the assessment of Fractional Flow Reserve (FFR) in the catheterization lab can be performed with equivalent accuracy when hyperemia is induced with IV Regadenoson compared with IV Adenosine without compromising patient safety.

more trials >>

Reports of Suspected Lexiscan (Regadenoson) Side Effects

Unresponsive TO Stimuli (16)Dyspnoea (14)Chest Pain (12)Cardiac Arrest (11)Hypotension (10)Respiratory Arrest (9)Bradycardia (9)Loss of Consciousness (7)Death (7)Acute Myocardial Infarction (7)more >>

Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014